Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

Big Science

The Economics of Big Science — and Why It Matters for Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biotech Funding

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

David Alvaro, Ph.D.

Pharma's Almanac

M&A

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

Pharma's Almanac

M&A

Fewer, Bigger, Smarter: How Pharma M&A Evolved in 2025 — and What Comes Next

David Alvaro, Ph.D.

Pharma's Almanac

GLP-1

How are GLP-1 therapies reshaping the pharmaceutical market — and what’s next?

Pharma's Almanac

API

What is driving renewed interest in small molecule therapeutics — and how is it shaping investment?

Pharma's Almanac

Global Growth

Beyond Borders: A Disciplined Approach to Successful Global Expansion

Eric B. Lev

Ampersand Capital Partners

Threats

What do you see as the biggest threat to the CDMO industry in 2026 or beyond?

Pharma's Almanac

Market Trends

What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?

Pharma's Almanac